Company Information

Company AstraZeneca UK Ltd
www.astrazeneca.com
Type:
Company
Country:
United Kingdom
Sector:
Pharmaceuticals & Biotechnology
Ownership:
Publicly Listed
Global Compact Status:
Active
Participant Since
08 January 2010
Letter of Commitment
Next Communication on Progress (COP) due on:
31 July 2024

Financial Information


Twitter Feed from AstraZeneca UK Ltd

Early Adopter

Enhanced Communication on Progress

Affiliated Subsidiaries

Country Company Name
Saudi Arabia AstraZeneca
Mexico AstraZeneca México
Egypt AstraZeneca Egypt
Sweden AstraZeneca AB
Malaysia AstraZeneca Sdn. Bhd.

Communication On Progress

Published On Title Level/Status
27-Dec-2023 2023 Communication on Progress Submitted
18-Jul-2022 2022 Communication on Progress Submitted
27-Jun-2022 Communication on Progress Advanced
31-Mar-2021 Communication on Progress 2020 Advanced
03-Apr-2020 Communication on Progress Advanced
04-Apr-2019 Communication on Progress AstraZeneca 2019 Advanced
23-Apr-2018 Communication on Progress Advanced
29-Apr-2017 Communication on Progress Active
06-Jun-2016 Communication on Progress AstraZeneca 2016 Active
10-Jun-2015 AstraZeneca Communication on Progress 2015 Learner
06-Mar-2015 Grace Letter Not applicable
28-Mar-2014 Communication on Progress 2014 Advanced
28-Mar-2013 AstraZeneca 2012 Advanced
28-Mar-2012 2011 Communication on Progress Advanced
08-Apr-2011 2010 Communication on Progress Advanced
21-Dec-2010 Grace Letter Not applicable

Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.

Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP, for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.